Travere pays Everest $112M upfront to grow rare kidney disease pipeline

Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings…

benzinga.com17 g fa

The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a…

biopharmadive.com1 mese fa

The FDA approved a kidney disease drug from Vera Therapeutics called Trutakna, to treat IgA nephropathy

statnews.com1 mese fa

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.

cnbc.com5 mesi fa

Zymeworks to acquire Theravance Biopharma for $929M, gaining rights to COPD drug Yupelri's US profit share and ex-US royalties…

endpoints.news1 mese fa

Vaderis Therapeutics raised a Series B to run a Phase 3 study of its AKT inhibitor engasertib in a rare blood disorder called…

endpoints.news11 g fa

Related reading